English

CNS Pharmaceuticals, Inc.

EDGAR

CNSP Quarterly report (10-Q) · filed 2026-08-12

50 filing records in this dataset, filed from 2019-06-28 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 20 million USD 2026-06-30 Source
Exact value

19985000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.46 million shares 2026-06-30 Source
Exact value

1461449 shares

Reported share-count change

189.73% · 957 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

504413 shares · 2025-06-30· Source
1461449 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-16.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -3218481 USD · 2025-07-01 – 2025-09-30 Source
Net income: -15850564 USD · 2025-01-01 – 2025-12-31 Source
Net income: -9894762 USD · 2025-01-01 – 2025-09-30 Source
Net income: -4937000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -2588000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 992,763

Prior period

−USD 14.86 million

2024-01-01 – 2024-12-31
Current period

−USD 15.85 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-15850564 − -14857801 = -992763 USD

-14857801 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-15850564 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Year-over-year change in Net income: -992763 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -15850564 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#537742 Filing: 000168316826002550 Input fundies:NetIncome: -14857801 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#538111 Filing: 000168316826002550
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.3 million

Prior period

−USD 17.11 million

2024-01-01 – 2024-12-31
Current period

−USD 13.81 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-13811107 − -17113299 = 3302192 USD

-17113299 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-13811107 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Year-over-year change in Operating cash flow: 3302192 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -13811107 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#545689 Filing: 000168316826002550 Input fundies:OperatingCashFlow: -17113299 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#546153 Filing: 000168316826002550
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+334%

Prior period

USD 4,188

2024-01-01 – 2024-12-31
Current period

USD 18,175

2025-01-01 – 2025-12-31

Exact inputs and evidence

18175 − 4188 = 13987 USD

4188 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
18175 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Year-over-year change in Capital expenditure: 13987 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 18175 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#547803 Filing: 000168316826002550 Input fundies:CapitalExpenditure: 4188 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#548264 Filing: 000168316826002550
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 7.39 million Exact value Exact value: -7391899 USD 2018-01-01 – 2018-12-31: -7391899 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2018-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -7391899 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7391899 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316820000781/cnsp-20191231.xml#64081 Filing: 000168316820000781 The citation records this snapshot. The page link may show a newer release later.	−USD 716,385 Exact value Exact value: -716385 USD 2018-01-01 – 2018-12-31: -716385 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2018-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -716385 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -716385 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316820000781/cnsp-20191231.xml#141095 Filing: 000168316820000781 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2018-01-01 – 2018-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2018-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316820000781/cnsp-20191231.xml#238146 Filing: 000168316820000781 The citation records this snapshot. The page link may show a newer release later.	−USD 716,385 Calculation and evidence -716385 − 0 USD Exact free cash flow: -716385 USD 2018-01-01 – 2018-12-31: -716385 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2018-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -716385 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -716385 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316820000781/cnsp-20191231.xml#141095 Filing: 000168316820000781 Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316820000781/cnsp-20191231.xml#238146 Filing: 000168316820000781 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 3.88 million Exact value Exact value: -3877211 USD 2019-01-01 – 2019-12-31: -3877211 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2019-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -3877211 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3877211 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#147476 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.	−USD 3.55 million Exact value Exact value: -3553472 USD 2019-01-01 – 2019-12-31: -3553472 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2019-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -3553472 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3553472 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154991 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.	USD 20,120 Exact value Exact value: 20120 USD 2019-01-01 – 2019-12-31: 20120 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2019-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 20120 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20120 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154624 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.	−USD 3.57 million Calculation and evidence -3553472 − 20120 USD Exact free cash flow: -3573592 USD 2019-01-01 – 2019-12-31: -3553472 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 20120 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2019-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -3573592 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3553472 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154991 Filing: 000168316821000533 Input fundies:CapitalExpenditure: 20120 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154624 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 9.46 million Exact value Exact value: -9457871 USD 2020-01-01 – 2020-12-31: -9457871 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2020-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -9457871 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9457871 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316822001401/cns_i10k-123121.htm#503993 Filing: 000168316822001401 The citation records this snapshot. The page link may show a newer release later.	−USD 7.32 million Exact value Exact value: -7318018 USD 2020-01-01 – 2020-12-31: -7318018 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2020-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -7318018 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7318018 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316822001401/cns_i10k-123121.htm#512568 Filing: 000168316822001401 The citation records this snapshot. The page link may show a newer release later.	USD 17,945 Exact value Exact value: 17945 USD 2020-01-01 – 2020-12-31: 17945 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2020-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 17945 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17945 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154442 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.	−USD 7.34 million Calculation and evidence -7318018 − 17945 USD Exact free cash flow: -7335963 USD 2020-01-01 – 2020-12-31: -7318018 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 17945 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2020-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -7335963 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7318018 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316822001401/cns_i10k-123121.htm#512568 Filing: 000168316822001401 Input fundies:CapitalExpenditure: 17945 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316821000533/cnsp-20201231.xml#154442 Filing: 000168316821000533 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 14.5 million Exact value Exact value: -14495200 USD 2021-01-01 – 2021-12-31: -14495200 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2021-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -14495200 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14495200 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316823002086/cns_i10k-2022.htm#548811 Filing: 000168316823002086 The citation records this snapshot. The page link may show a newer release later.	−USD 13.54 million Exact value Exact value: -13538309 USD 2021-01-01 – 2021-12-31: -13538309 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2021-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -13538309 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13538309 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316823002086/cns_i10k-2022.htm#557356 Filing: 000168316823002086 The citation records this snapshot. The page link may show a newer release later.	USD 5,748 Exact value Exact value: 5748 USD 2021-01-01 – 2021-12-31: 5748 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2021-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 5748 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5748 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316823002086/cns_i10k-2022.htm#559440 Filing: 000168316823002086 The citation records this snapshot. The page link may show a newer release later.	−USD 13.54 million Calculation and evidence -13538309 − 5748 USD Exact free cash flow: -13544057 USD 2021-01-01 – 2021-12-31: -13538309 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 5748 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2021-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -13544057 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13538309 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316823002086/cns_i10k-2022.htm#557356 Filing: 000168316823002086 Input fundies:CapitalExpenditure: 5748 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316823002086/cns_i10k-2022.htm#559440 Filing: 000168316823002086 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 15.27 million Exact value Exact value: -15274134 USD 2022-01-01 – 2022-12-31: -15274134 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2022-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -15274134 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15274134 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002032/cnspharma_i10k-123123.htm#559202 Filing: 000168316824002032 The citation records this snapshot. The page link may show a newer release later.	−USD 10.56 million Exact value Exact value: -10557815 USD 2022-01-01 – 2022-12-31: -10557815 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2022-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -10557815 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10557815 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002032/cnspharma_i10k-123123.htm#567242 Filing: 000168316824002032 The citation records this snapshot. The page link may show a newer release later.	USD 4,422 Exact value Exact value: 4422 USD 2022-01-01 – 2022-12-31: 4422 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2022-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 4422 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4422 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002032/cnspharma_i10k-123123.htm#569345 Filing: 000168316824002032 The citation records this snapshot. The page link may show a newer release later.	−USD 10.56 million Calculation and evidence -10557815 − 4422 USD Exact free cash flow: -10562237 USD 2022-01-01 – 2022-12-31: -10557815 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4422 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2022-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -10562237 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10557815 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002032/cnspharma_i10k-123123.htm#567242 Filing: 000168316824002032 Input fundies:CapitalExpenditure: 4422 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002032/cnspharma_i10k-123123.htm#569345 Filing: 000168316824002032 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 18.85 million Exact value Exact value: -18851226 USD 2023-01-01 – 2023-12-31: -18851226 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2023-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -18851226 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18851226 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm#597964 Filing: 000168316825002139 The citation records this snapshot. The page link may show a newer release later.	−USD 14.14 million Exact value Exact value: -14140031 USD 2023-01-01 – 2023-12-31: -14140031 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2023-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -14140031 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14140031 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm#606417 Filing: 000168316825002139 The citation records this snapshot. The page link may show a newer release later.	USD 3,901 Exact value Exact value: 3901 USD 2023-01-01 – 2023-12-31: 3901 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2023-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 3901 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3901 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm#608557 Filing: 000168316825002139 The citation records this snapshot. The page link may show a newer release later.	−USD 14.14 million Calculation and evidence -14140031 − 3901 USD Exact free cash flow: -14143932 USD 2023-01-01 – 2023-12-31: -14140031 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3901 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2023-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -14143932 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14140031 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm#606417 Filing: 000168316825002139 Input fundies:CapitalExpenditure: 3901 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316825002139/cns_i10k-123124.htm#608557 Filing: 000168316825002139 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 14.86 million Exact value Exact value: -14857801 USD 2024-01-01 – 2024-12-31: -14857801 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2024-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -14857801 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14857801 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#538111 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	−USD 17.11 million Exact value Exact value: -17113299 USD 2024-01-01 – 2024-12-31: -17113299 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2024-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -17113299 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17113299 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#546153 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	USD 4,188 Exact value Exact value: 4188 USD 2024-01-01 – 2024-12-31: 4188 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2024-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 4188 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4188 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#548264 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	−USD 17.12 million Calculation and evidence -17113299 − 4188 USD Exact free cash flow: -17117487 USD 2024-01-01 – 2024-12-31: -17113299 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 4188 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2024-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -17117487 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17113299 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#546153 Filing: 000168316826002550 Input fundies:CapitalExpenditure: 4188 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#548264 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 15.85 million Exact value Exact value: -15850564 USD 2025-01-01 – 2025-12-31: -15850564 USD Inspect Net Income Open source Share or cite Citation for Net Income · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Net Income: -15850564 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15850564 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#537742 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	−USD 13.81 million Exact value Exact value: -13811107 USD 2025-01-01 – 2025-12-31: -13811107 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Operating Cash Flow: -13811107 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13811107 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#545689 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	USD 18,175 Exact value Exact value: 18175 USD 2025-01-01 – 2025-12-31: 18175 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Capital Expenditure: 18175 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18175 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#547803 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.	−USD 13.83 million Calculation and evidence -13811107 − 18175 USD Exact free cash flow: -13829282 USD 2025-01-01 – 2025-12-31: -13811107 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 18175 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CNS Pharmaceuticals, Inc. · 2025-12-31 CNS Pharmaceuticals, Inc. (edgar:1729427) Free cash flow: -13829282 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:09:44Z Snapshot: f831c2888d9c206a7fcef4f5f6146a60907ec911ccce553d5631e327b4d240b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1729427?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13811107 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#545689 Filing: 000168316826002550 Input fundies:CapitalExpenditure: 18175 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1729427/000168316826002550/cns_i10k-123125.htm#547803 Filing: 000168316826002550 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

50 filings · 1,490 latest values · 1,490 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001729427, 1729427, CNSP, edgar:1729427

Also known as CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation